Novo Nordisk, a healthcare company, completed the acquisition of Dicerna, a biopharmaceutical company, for $3.3bn. “The acquisition of Dicerna accelerates Novo Nordisk’s research within RNAi and expands the usage of the RNAi technology. We build on our successful collaboration and by combining Dicerna’s state-of-the-art RNAi drug engine and intracellular delivery with our deep capabilities in disease biology understanding and tissue targeting through peptides and proteins we have the potential to expand our pipeline and deliver life-changing precision medicines for people living with chronic diseases such as diabetes, obesity, cardiovascular disease and NASH, as well as rare diseases like endocrine disorders and bleeding disorders," Marcus Schindler, Novo Nordisk Executive Vice President and Chief Scientific Officer.